By Colin Kellaher
Keros Therapeutics is slashing its workforce by 45% as part of a restructuring following a decision by the clinical-stage biopharmaceutical company to end development of its cibotercept product candidate in pulmonary arterial hypertension, or PAH.
Keros on Thursday said it will have 85 full-time employees after the job cuts, adding that it expects about $17 million in average annualized cost savings.
The Lexington, Mass., company said it expects to incur about $3.2 million in cash charges associated with the reorganization, which it expects to complete by the end of the year.
Keros late last year halted two treatment arms in a Phase 2 study of cibotercept in PAH based on the observation of pericardial effusions, and it stopped all dosing in the trial in January based on a safety review due to new observations of pericardial effusion adverse events.
Keros, which in April said it was reviewing alternatives aimed at maximizing shareholder value, including a possible sale, on Thursday said it plans to provide a preliminary update on the review process by June 9.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 29, 2025 07:37 ET (11:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.